Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
25/06/2026 08:01
BRIEF-Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S. June 25 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
IONIS ANNOUNCES LICENSE AGREEMENT WITH RECORDATI FOR ZILGANERSEN IN ALEXANDER DISEASE (AXD) IN ALL COUNTRIES OUTSIDE THE U.S.
IONIS PHARMACEUTICALS - TO RETAIN U.S. COMMERCIAL RIGHTS AND LEAD GLOBAL DEVELOPMENT OF ZILGANERSEN
IONIS PHARMACEUTICALS - PLANS INDEPENDENT U.S. LAUNCH OF ZILGANERSEN; FDA PDUFA DATE SET FOR SEPTEMBER 22
Source text: ID:nBwb537Nya
Further company coverage: IONS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors